59,460 results match your criteria Myeloma


Clinical outcomes of bortezomib-based therapy in myeloma.

PLoS One 2018 12;13(12):e0208920. Epub 2018 Dec 12.

Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Bortezomib, a first generation proteasome inhibitor, is used in both newly diagnosed and relapsed myeloma settings. Considerable differences exist in the usage of bortezomib therapy in the clinical practice setting in comparison to clinical trial setting as well manufacturer's recommendations. These differences include route of administration (intravenous (iv) vs. Read More

View Article
December 2018

PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma.

PLoS One 2018 12;13(12):e0207908. Epub 2018 Dec 12.

SBILab, Department of ECE, Indraprastha Institute of Information Technology-Delhi (IIIT-Delhi), New Delhi, India.

Plasma cell segmentation is the first stage of a computer assisted automated diagnostic tool for multiple myeloma (MM). Owing to large variability in biological cell types, a method for one cell type cannot be applied directly on the other cell types. In this paper, we present PCSeg Tool for plasma cell segmentation from microscopic medical images. Read More

View Article
December 2018

Antigen-Specific Human Monoclonal Antibodies from Transgenic Mice.

Methods Mol Biol 2019 ;1904:253-291

Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain.

Due to the difficulties found when generating fully human monoclonal antibodies (mAbs) by the traditional method, several efforts have attempted to overcome these problems, with varying levels of success. One approach has been the development of transgenic mice carrying immunoglobulin (Ig) genes in germline configuration. The engineered mouse genome can undergo productive rearrangement in the B-cell population, with the generation of mouse B lymphocytes expressing human Ig (hIg) chains. Read More

View Article
January 2019

Isolation of Antigen-Specific, Antibody-Secreting Cells Using a Chip-Based Immunospot Array.

Methods Mol Biol 2019 ;1904:147-162

Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Antigen-specific monoclonal antibodies are useful tools to detect very small amounts of antigenic materials and are applicable for antibody therapeutics. To produce mouse monoclonal antibodies, a hybridoma between B lymphocytes and myeloma cells is used to produce antigen-specific monoclonal antibodies. However, a good hybridoma system is not available to obtain human monoclonal antibodies. Read More

View Article
January 2019

Simplified novel prognostic score for real-life older adults with multiple myeloma-registry-based analysis.

Ann Hematol 2018 Dec 11. Epub 2018 Dec 11.

4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Králové, Czech Republic.

The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65 years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65 years with symptomatic myeloma were included. Read More

View Article
December 2018

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.

Ann Hematol 2018 Dec 11. Epub 2018 Dec 11.

Department of Medicine, Institute of Radiology, Padua University School of Medicine, Padua, Italy.

We evaluated differences in density and F-FDG PET/MRI features of lytic bone lesions (LBLs) identified by whole-body low-dose CT (WB-LDCT) in patients affected by newly diagnosed multiple myeloma (MM). In 18 MM patients, 135 unequivocal LBLs identified by WB-LDCT were characterized for inner density (negative or positive Hounsfield unit (HU)), where negative density (HU < 0) characterizes normal yellow marrow whereas positive HU correlates with tissue-like infiltrative pattern. The same LBLs were analyzed by F-FDG PET/DWI-MRI, registering DWI signal with ADC and SUV max values. Read More

View Article
December 2018

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Front Immunol 2018 27;9:2749. Epub 2018 Nov 27.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Read More

View Article
November 2018

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Blood Cancer J 2018 Dec 11;8(12):125. Epub 2018 Dec 11.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. Read More

View Article
December 2018

The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Loyola University Medical Center, Internal Medicine, 2160 S 1(st) Ave, IL, Maywood, Illinois 60153, United States.

Multiple myeloma (MM) is a malignant disorder of plasma cells primarily affecting elderly patients and is the second most commonly diagnosed hematological neoplasm. With the recent influx of effective new agents available including proteasome inhibitors, immunomodulators, targeted monoclonal antibodies, and now chimeric antigen receptor t-cell therapy (CAR-T), the treatment landscape is evolving rapidly. While the role of consolidative autologous stem cell transplantation (ASCT) in first remission is well established, in the relapsed setting following up front ASCT, the role of a second ASCT (SAT) following reinduction is less clear and understudied. Read More

View Article
December 2018

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States.

Cancer Med 2018 Dec 8. Epub 2018 Dec 8.

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Background: Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal-related events for patients diagnosed with multiple myeloma (MM). We examined patterns of IV BP initiation and interruption among patients with newly diagnosed MM (NDMM) in the United States.

Methods: Electronic health records linked to administrative health insurance claims were used to identify adults with NDMM between 1 January 2011 and 30 April 2016. Read More

View Article
December 2018

Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis.

Am J Hematol 2018 Dec 8. Epub 2018 Dec 8.

Stanford Cancer Institute, Stanford University Medical Center.

View Article
December 2018

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Cytometry A 2018 Dec 11. Epub 2018 Dec 11.

Janssen Research & Development, Beerse, Belgium.

Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell expansion and reduction of immune-suppressive populations, suggesting immune modulation as an additional mechanism of action. Here, we performed an in-depth analysis of the effects of daratumumab on immune-cell subpopulations using high-dimensional mass cytometry. Read More

View Article
December 2018
1 Read

[Pathogenesis of multiple myeloma].

Authors:
L Rasche N Weinhold

Internist (Berl) 2018 Dec 10. Epub 2018 Dec 10.

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Background: Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal plasma cells infiltrating the bone marrow thereby causing anemia and lytic bone lesions. Despite significant improvement in overall survival, most MM patients inevitably, yet unpredictably, develop refractory disease and MM remains largely incurable.

Objective: This article describes the stages of progression and presents current insights into the pathogenesis of MM. Read More

View Article
December 2018

[Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].

Internist (Berl) 2018 Dec 10. Epub 2018 Dec 10.

Medizinische Klinik 2, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97074, Würzburg, Deutschland.

The treatment of multiple myeloma remains in a state of profound change. Over the past decades both disease-free survival and overall survival have been significantly prolonged by the approval of new drugs; however, despite high response rates and achievement of deep responses to primary treatment, recurrence of the disease is still expected in nearly all patients treated. Fortunately, good treatment options for myeloma patients in relapse are also currently available and the possible combinations of approved substances are numerous. Read More

View Article
December 2018
2 Reads

MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.

Int J Mol Med 2018 Dec 7. Epub 2018 Dec 7.

Department of Hematology, Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong 518172, P.R. China.

Multiple myeloma (MM) is a common severe hematopoietic malignancy occuring in aged population. MicroRNA (miR)‑497 was previously reported to contribute to the apoptosis of other cell types, presumably through targeting B‑cell lymphoma 2 (Bcl‑2). In the present study, miRNA and protein expression levels were detected by reverse transcription‑quantitative polymerase chain reaction and western blot analyses, respectively. Read More

View Article
December 2018

[Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016].

Rev Med Chil 2018 Jul;146(7):869-875

Hospital Barros Luco Trudeau, Santiago, Chile.

Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology.

Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016.

Material And Methods: Analysis of the database of the Chilean national anti-neoplastic drug program. Read More

View Article

Chondrosarcoma of the pelvis - case report.

Rom J Morphol Embryol 2018 ;59(3):927-931

Department of Obstetrics and Gynecology, University Emergency Hospital of Bucharest, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania;

Chondrosarcoma (CHS) is the third most common primary bone tumor after myeloma and osteosarcoma. Histologically, it is made of pure hyaline cartilage differentiation. The tumor itself may have myxoid modification and calcification. Read More

View Article
January 2018

Screening for Humoral Immunodefi ciency in Patients with Community-Acquired Pneumonia.

J Hosp Med 2018 Nov 28. Epub 2018 Nov 28.

Rochester Regional Health, Rochester, New York, USA.

Background: Immunodeficiency is an underrecognized risk factor for infections, such as community-acquired pneumonia (CAP).

Objective: We evaluated patients admitted with CAP for humoral immunodeficiency.

Design: Prospective Cohort Study. Read More

View Article
November 2018
1 Read

The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.

Biomed Res Int 2018 11;2018:3936706. Epub 2018 Nov 11.

Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

The VAD (vincristine-doxorubicin-dexamethasone) regimen has been used for decades to treat multiple myeloma (MM). Based on reports that vascular endothelial growth factor- (VEGF-) mediated angiogenesis is critical for MM pathogenesis, the antiangiogenic compound thalidomide has been added to VAD (T-VAD). However, it remains unclear whether T-VAD is more efficacious than VAD for serum VEGF reduction or if the difference influences clinical outcome. Read More

View Article
November 2018

Toxoplasma Encephalitis following Tandem Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature.

Case Rep Infect Dis 2018 11;2018:9409121. Epub 2018 Nov 11.

University of Iowa, Department of Internal Medicine, Division of Infectious Diseases, Iowa City, IA, USA.

Infection with is a rare but often fatal complication in hematopoietic stem cell transplantation (HSCT) recipients. Most cases have been reported in allogeneic (allo-) HSCT recipients, with only narrative reports following autologous HSCT (ASCT). We report the case of a 58-year-old Caucasian male presenting with toxoplasma encephalitis following tandem ASCT for myeloma and successfully treated with diagnosis by polymerase chain reaction analysis of cerebrospinal fluid. Read More

View Article
November 2018

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma.

Oncotarget 2018 Nov 9;9(88):35801-35802. Epub 2018 Nov 9.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

View Article
November 2018

[Syndrome of inappropriate secretion of antidiuretic hormone in multiple myeloma patients treated with bortezomib, lenalidomide, and dexamethasone combination therapy].

Rinsho Ketsueki 2018 ;59(11):2423-2427

Division of Hematology, Department of Medicine, Showa University School of Medicine.

Hyponatremia occurs while receiving bortezomib-containing combination therapy in multiple myeloma (MM) ; however, the mechanism of hyponatremia remains unclear. A 65-year-old female with MM was treated with bortezomib, lenalidomide, and dexamethasone. Fourteen days after chemotherapy initiation, she developed hyponatremia (serum sodium, 127 mEq/l, compared with 136 mEq/l before chemotherapy) with plasma hypo-osmolality and urine hyper-osmolality. Read More

View Article
January 2018

[Safety and management of adverse events of ixazomib/lenalidomide/dexamethasone therapy in Japanese patients with relapsed/refractory multiple myeloma].

Rinsho Ketsueki 2018 ;59(11):2399-2407

Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited.

Based on the outcomes of the TOURMALINE-MM1 trial-a global, randomized, double-blind, placebo-controlled phase III clinical study-the use of an oral proteasome inhibitor has been approved in combination with lenalidomide and dexamethasone (Rd) for the treatment of relapsed/refractory multiple myeloma (MM). In this study, we enrolled 41 Japanese patients, who constituted the safety population. The overall incidence of adverse events (AEs) was similar in IRd and placebo-Rd groups. Read More

View Article
January 2018

p53 regulates CD46 expression and measles virus infection in myeloma cells.

Blood Adv 2018 Dec;2(23):3492-3505

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

In this study, we assessed the sensitivity of myeloma cells to the oncolytic measles virus (MV) in relation to p53 using 37 cell lines and 23 primary samples. We showed that infection and cell death were correlated with CD46 expression, which was associated with status; cell lines highly expressed CD46 and were preferentially infected by MV when compared with the cell lines ( = .046 and = . Read More

View Article
December 2018

Multiple myeloma in paleopathology: A critical review.

Int J Paleopathol 2018 Dec 6;24:201-212. Epub 2018 Dec 6.

Division of Paleopathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy.

This paper provides a critical literature review concerning paleopathological evidence of multiple myeloma discovered both in the Old and in the New World. A critical assessment of the bioarchaeological and paleopathological documentary sources permitted to identify a total of 25 ascertained cases of multiple myeloma from different geographical areas in the world ranging from Prehistoric times up to the Contemporary age. The distribution of multiple myeloma findings in past times shows that the majority of cases have been discovered in the Old World (n = 18) and extend back to the Middle Ages, while the evidences in the New World (n = 7) seems to date back to the pre-Columbian era. Read More

View Article
December 2018

Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.

Biochem Pharmacol 2018 Dec 7. Epub 2018 Dec 7.

Department of Biochemistry and Molecular Biology, Ajou University, Suwon 16499 Korea; Department of Biomedical Science, Ajou University Graduate School of Medicine, Suwon 16499 Korea. Electronic address:

Although the proteasome inhibitor (PI) bortezomib (Btz) is in current clinical use as a front-line treatment for multiple myeloma, its clinical efficacy in solid tumors has not been satisfactory. Here, we show that loperamide (Lop), an antidiarrheal drug, effectively sensitizes various colon cancer cells, but not normal epithelial cells, to PI-mediated cell death. We report that combined treatment with Btz and Lop induces paraptosis-like cell death accompanied by severe endoplasmic reticulum (ER)-derived vacuolation. Read More

View Article
December 2018

Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.

Eur J Med Chem 2018 Nov 16;163:281-294. Epub 2018 Nov 16.

Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. Electronic address:

Bromodomain-containing protein 4 (BRD4), an epigenetic reader of acetyl lysine, has emerged as a promising therapeutic target for many diseases including cancer, inflammation and heart failure. Our previous study reported that nitroxoline, an FDA approved antibiotic, showed potential BRD4 inhibitory activity and antiproliferation activity against leukemia cell lines. In this study, we further explored the structure-activity relationship (SAR) around nitroxoline and employed our previously developed machine learning based activity scoring function BRD4LGR for further analysis. Read More

View Article
November 2018
2 Reads

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?

Neoplasia 2018 Dec 4;21(1):93-105. Epub 2018 Dec 4.

Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy.

Interactions of multiple myeloma (MM) cells with endothelial cells (ECs) enhance angiogenesis and MM progression. Here, we investigated the role of Notch signaling in the cross talk between ECs and MM cells enabling angiogenesis. MMECs showed higher expression of Jagged1/2 ligands, of activated Notch1/2 receptors, and of Hes1/Hey1 Notch target genes than ECs from monoclonal gammopathy of undetermined significance patients, suggesting that homotypic activation of Notch pathway occurs in MM. Read More

View Article
December 2018

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

Blood Rev 2018 Nov 14. Epub 2018 Nov 14.

Experimental Transplantation and Immunology Branch, National Cancer Institute, Building 10, Suite 3-3330, Bethesda, MD 20892, United States. Electronic address:

Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. Read More

View Article
November 2018

Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2018 Nov 12. Epub 2018 Nov 12.

Stem Cell Transplant Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH. Electronic address:

Introduction: Induction chemotherapy with cytarabine and an anthracycline (7+3) remains the standard of care for acute myeloid leukemia (AML).

Patients And Methods: We retrospectively analyzed 183 newly diagnosed AML patients to compare the utility of rapid peripheral blast clearance (PBC), day of peripheral blast disappearance, residual blasts, and cellularity at day 14 bone marrow biopsy (D14BM) in predicting clinical response to 7+3 induction, overall survival (OS), and relapse-free survival (RFS).

Results: In multivariable logistic regression analysis, day 2 PBC > 85% [P = . Read More

View Article
November 2018

Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas.

Cancer Epidemiol 2018 Dec 5;58:89-97. Epub 2018 Dec 5.

Department of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Electronic address:

Background: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013.

Methods: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Read More

View Article
December 2018
1 Read

Total Skin Electron Beam Therapy for Mycosis Fungoides Revisited With Adjuvant Systemic Therapy.

Clin Lymphoma Myeloma Leuk 2018 Nov 17. Epub 2018 Nov 17.

Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address:

Background: Although standard-dose total skin electron beam therapy (TSEBT) has been thought to provide the greatest clinical benefit for mycosis fungoides, recent studies have shown that low-dose TSEBT may also provide high rates of disease control.

Materials And Methods: A retrospective chart review was conducted for patients receiving TSEBT for mycosis fungoides at a single institution from 2009 to 2017. Patients were evaluated for overall survival, progression-free survival, and duration of clinical benefit. Read More

View Article
November 2018

Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.

Clin Lymphoma Myeloma Leuk 2018 Nov 17. Epub 2018 Nov 17.

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA.

Introduction: Intrathecal chemoprophylaxis is often administered to patients with diffuse large B-cell lymphoma (DLBCL) to lower the rates of central nervous system (CNS) relapse, although its benefit has not been well-described. Prognostic models, including the CNS-International Prognostic Index (IPI), have been developed to aid in identifying patients at highest risk for CNS relapse.

Patients And Methods: We evaluated 112 patients diagnosed with DLBCL from 2009 to 2016 at Emory Healthcare and classified them as high (n = 44) or low risk (n = 68) for CNS relapse and compared CNS prophylaxis rates and relapse rates between groups. Read More

View Article
November 2018

Special problems in the management of elderly patients with multiple myeloma.

Eur J Intern Med 2018 Dec;58:64-69

Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Multiple myeloma (MM) is a neoplastic disease typical of the elderly. Many steps forward have been made in the characterization of patients, and new treatment strategies are available today. Clinical trials represent a major point in the definition of standard treatment, although they usually include fit patients, while frail patients are commonly excluded. Read More

View Article
December 2018

Current role of high dose chemotherapy in the management of multiple myeloma.

Authors:
Morie A Gertz

Leuk Lymphoma 2018 Dec 11:1-3. Epub 2018 Dec 11.

a Division of Hematology, Department of Medicine, College of Medicine , Mayo Clinic , Rochester , MN , USA.

View Article
December 2018

Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain.

Cell Physiol Biochem 2018 6;51(5):2098-2110. Epub 2018 Dec 6.

Background/aims: Bortezomib (BTZ) is largely used as a chemotherapeutic agent for the treatment of multiple myeloma. However, one of the significant limiting complications of BTZ is painful peripheral neuropathy during BTZ therapy. The purpose of this study was to examine the underlying mechanisms leading to neuropathic pain induced by BTZ. Read More

View Article
December 2018
1 Read

Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.

Authors:
Eden Lake

J Am Acad Dermatol 2018 Dec 3. Epub 2018 Dec 3.

Loyola University Medical Center Dermatology, 321 N La Grange Rd, La Grange Park, IL. Electronic address:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts. Read More

View Article
December 2018
5 Reads

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

J Cancer Res Clin Oncol 2018 Dec 5. Epub 2018 Dec 5.

Division of Hematology and Medical Oncology, Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany.

Based on ELOQUENT-2, combination therapy with the monoclonal antibody elotuzumab was approved for relapsed/refractory multiple myeloma in the US and Europe. However, outside clinical trials, the optimal integration of elotuzumab into the sequence of treatment lines remains to be determined. Therefore, we analyzed safety and efficacy of elotuzumab/immunomodulatory drug combinations in a real-life cohort of 33 patients from our institution. Read More

View Article
December 2018

Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement.

Case Rep Oncol 2018 Sep-Dec;11(3):721-728. Epub 2018 Nov 12.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Involvement of the central nervous system (CNS) by mycosis fungoides (MF) is rare; however, it portends a poor prognosis. While aggressive multimodality therapy may improve outcomes, the role of radiation therapy (RT) is not well defined.

Objectives: We sought to explore the efficacy of RT in the management of CNS involvement by MF. Read More

View Article
November 2018

Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?

Patient Prefer Adherence 2018 9;12:2387-2396. Epub 2018 Nov 9.

Asklepios Kliniken Hamburg GmbH, 22763 Hamburg, Germany.

Background And Objectives: This study describes preferences of German relapsed refractory multiple myeloma (RRMM) patients with novel proteasome inhibitor-based combination treatments.

Methods: Patients with a minimum age of 18 years and a diagnosis of RRMM were included. Their preferences were assessed using a discrete choice experiment design, which was developed based on a literature review and two patient focus group discussions. Read More

View Article
November 2018
1 Read

Cell-based immunotherapy approaches for multiple myeloma.

Br J Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

Despite the arrival of novel therapies, multiple myeloma (MM) remains incurable and new treatment options are needed. Chimeric antigen receptor (CAR) T cells are genetically modified T cells that express a CAR directed against specific tumour antigens. CAR T cells are able to kill target tumour cells and may result in long-lasting immune responses in vivo. Read More

View Article
December 2018

BK channel blocker paxilline attenuates thalidomide-caused synaptic and cognitive dysfunctions in mice.

Sci Rep 2018 Dec 5;8(1):17653. Epub 2018 Dec 5.

Department of Physiology and Dental Research Institute, Seoul National University School of Dentistry, Seoul, 03080, Republic of Korea.

Thalidomide is a widely prescribed immunomodulatory drug (iMiD) for multiple myeloma, but causes reversible memory loss in humans. However, how thalidomide causes cognitive dysfunction at a cellular and molecular level has not been demonstrated. We studied the effect of thalidomide on synaptic functions and cognitive behaviors using a mouse model. Read More

View Article
December 2018
1 Read

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Front Immunol 2018 16;9:2431. Epub 2018 Nov 16.

Department of Haematooncology, University Hospital Ostrava, Ostrava, Czechia.

The treatment of cancer, especially of various types of solid tumors, has been revolutionized by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success amongst hematologic malignancies, however, has been limited so far to the treatment of classic Hodgkin's lymphoma, which portrays a typical overexpression of PD-1 ligands (PD-L1, PD-L2) as a consequence of changes in chromosome 9p24.1. Read More

View Article
November 2018
1 Read

Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors.

Sci Rep 2018 Nov 30;8(1):17520. Epub 2018 Nov 30.

Unit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Blood vessel micro-angioarchitecture plays a pivotal role in tumor progression, metastatic dissemination and response to therapy. Thus, methods able to quantify microvascular trees and their anomalies may allow a better comprehension of the neovascularization process and evaluation of vascular-targeted therapies in cancer. To this aim, the development of a restricted set of indexes able to describe the arrangement of a microvascular tree is eagerly required. Read More

View Article
November 2018

Novel immunotherapy approaches to follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):194-199

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Follicular lymphoma (FL) remains a lymphoma subtype that is remarkably sensitive to immunotherapy-based treatment strategies. Anti-CD20 antibody therapy administered as a single agent and in combination as a first-line treatment and at relapse continues to be the most broadly used therapy for this disease. Autologous and allogeneic stem cell transplantation provide meaningful durable remissions for patients with FL. Read More

View Article
November 2018

Sequencing of therapies in relapsed follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):189-193

Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY.

Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options. Despite the abundance of efficacious treatment modalities, there is no universally agreed upon standard approach to treatment, particularly in the relapsed/refractory setting. There is an increasing need for more robust and clinically available tools to risk-stratify patients and identify those likely to experience early relapse, which is currently recognized as the unmet need in FL. Read More

View Article
November 2018
2 Reads

Where to start? Upfront therapy for follicular lymphoma in 2018.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):185-188

Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

The initial approach to the management of follicular lymphoma (FL) is challenging for patients and physicians. Most FL patients present with minimal symptoms; given the lack of a survival benefit to early treatment in this population, a period of observation without therapy is often appropriate. Once there is disease progression beyond low-tumor-burden criteria or symptoms prompting intervention, patients may be considered for an array of potential treatment options. Read More

View Article
November 2018
7 Reads